JP2023517611A5 - - Google Patents
Info
- Publication number
- JP2023517611A5 JP2023517611A5 JP2022554632A JP2022554632A JP2023517611A5 JP 2023517611 A5 JP2023517611 A5 JP 2023517611A5 JP 2022554632 A JP2022554632 A JP 2022554632A JP 2022554632 A JP2022554632 A JP 2022554632A JP 2023517611 A5 JP2023517611 A5 JP 2023517611A5
- Authority
- JP
- Japan
- Prior art keywords
- approximately
- composition
- antibody
- use according
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062987837P | 2020-03-10 | 2020-03-10 | |
| US62/987,837 | 2020-03-10 | ||
| US202063006612P | 2020-04-07 | 2020-04-07 | |
| US63/006,612 | 2020-04-07 | ||
| US202063014800P | 2020-04-24 | 2020-04-24 | |
| US63/014,800 | 2020-04-24 | ||
| PCT/EP2021/056113 WO2021180821A2 (en) | 2020-03-10 | 2021-03-10 | Compositions of il-6/il-6r antibodies and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023517611A JP2023517611A (ja) | 2023-04-26 |
| JP2023517611A5 true JP2023517611A5 (https=) | 2024-03-19 |
Family
ID=74871406
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022554632A Pending JP2023517611A (ja) | 2020-03-10 | 2021-03-10 | Ｉｌ－６／ｉｌ－６ｒ抗体の組成物及びその使用方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20210284743A1 (https=) |
| EP (1) | EP4117727A2 (https=) |
| JP (1) | JP2023517611A (https=) |
| CN (1) | CN115697403A (https=) |
| AU (1) | AU2021234094A1 (https=) |
| CA (1) | CA3169827A1 (https=) |
| IL (1) | IL296276A (https=) |
| WO (1) | WO2021180821A2 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230174640A1 (en) * | 2020-03-18 | 2023-06-08 | Vitaeris Inc. | Use of Anti-IL-6 Antibody, e.g., Clazakizumab for Treatment/Prevention of ARDS Associated with Coronavirus (COVID-19) Infection |
| WO2022006051A1 (en) * | 2020-06-29 | 2022-01-06 | Anovent Pharmaceutical (U.S.), Llc | Formulation of tocilizumab and method for treating covid-19 by inhalation |
| CN116406274B (zh) * | 2020-07-30 | 2026-02-17 | 迪赞纳生命科学公开有限公司 | 用于治疗冠状病毒的cd3抗体 |
| US12552861B2 (en) * | 2021-10-08 | 2026-02-17 | National Taiwan University | Monoclonal antibody |
| WO2025122924A1 (en) * | 2023-12-07 | 2025-06-12 | Tourmaline Bio, Inc. | Methods for the prevention and treatment of long covid and related symptoms |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4654210A (en) | 1979-04-26 | 1987-03-31 | Ortho Pharmaceutical Corporation | Methods and compositions using complement fixing monoclonal antibody to human T cells |
| US4361549A (en) | 1979-04-26 | 1982-11-30 | Ortho Pharmaceutical Corporation | Complement-fixing monoclonal antibody to human T cells, and methods of preparing same |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4978745A (en) | 1987-11-23 | 1990-12-18 | Centocor, Inc. | Immunoreactive heterochain antibodies |
| US4975369A (en) | 1988-04-21 | 1990-12-04 | Eli Lilly And Company | Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen |
| US6406696B1 (en) | 1989-10-27 | 2002-06-18 | Tolerance Therapeutics, Inc. | Methods of stimulating the immune system with anti-CD3 antibodies |
| WO1991006319A1 (en) | 1989-10-27 | 1991-05-16 | Arch Development Corporation | Methods and compositions for promoting immunopotentiation |
| US5151510A (en) | 1990-04-20 | 1992-09-29 | Applied Biosystems, Inc. | Method of synethesizing sulfurized oligonucleotide analogs |
| US6491916B1 (en) | 1994-06-01 | 2002-12-10 | Tolerance Therapeutics, Inc. | Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies |
| CN101721362B (zh) * | 2002-02-14 | 2018-07-03 | 中外制药株式会社 | 包含抗体的溶液制剂 |
| US7713440B2 (en) | 2003-10-08 | 2010-05-11 | Lyotropic Therapeutics, Inc. | Stabilized uncoated particles of reversed liquid crystalline phase materials |
| CA2674608A1 (en) * | 2007-01-09 | 2008-07-17 | Wyeth | Anti-il-13 antibody formulations and uses thereof |
| MX2010012031A (es) | 2008-05-13 | 2011-01-20 | Novimmune Sa | Anticuerpos anti-il-6/il-6r y metodos de uso de los mismos. |
| KR102607829B1 (ko) * | 2015-03-30 | 2023-12-01 | 다케다 파머수티컬 컴패니 리미티드 | 혈장 칼리크레인 저해제 및 유전성 혈관부종 발작을 예방하기 위한 이의 용도 |
| CN116617387A (zh) * | 2016-08-29 | 2023-08-22 | 迪赞纳生命科学公开有限公司 | 抗cd3抗体制剂 |
| CA3031691A1 (en) | 2016-09-13 | 2018-03-22 | Rasna Research Inc. | Dactinomycin compositions and methods for the treatment of myelodysplastic syndrome and acute myeloid leukemia |
| KR20190078572A (ko) * | 2016-10-31 | 2019-07-04 | 프레제니우스 카비 도이치란트 게엠베하 | 액상의 약학 조성물 |
| US10093731B2 (en) * | 2017-02-24 | 2018-10-09 | Kindred Biosciences, Inc. | Anti-IL31 antibodies for veterinary use |
-
2021
- 2021-03-10 IL IL296276A patent/IL296276A/en unknown
- 2021-03-10 CA CA3169827A patent/CA3169827A1/en active Pending
- 2021-03-10 EP EP21711543.5A patent/EP4117727A2/en active Pending
- 2021-03-10 CN CN202180034449.8A patent/CN115697403A/zh active Pending
- 2021-03-10 WO PCT/EP2021/056113 patent/WO2021180821A2/en not_active Ceased
- 2021-03-10 JP JP2022554632A patent/JP2023517611A/ja active Pending
- 2021-03-10 AU AU2021234094A patent/AU2021234094A1/en active Pending
- 2021-03-10 US US17/197,603 patent/US20210284743A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023517611A5 (https=) | ||
| KR102390714B1 (ko) | 벤랄리주맙을 이용하여 천식의 악화 속도를 감소시키는 방법 | |
| KR102337599B1 (ko) | 벤랄리주맙을 이용하여 천식 환자에서 강제 호기량을 증가시키는 방법 | |
| US20230201497A1 (en) | Method for pulsatile delivery of a gaseous drug | |
| JP2023546503A5 (https=) | ||
| CN116406274B (zh) | 用于治疗冠状病毒的cd3抗体 | |
| JP2023535792A5 (https=) | ||
| JP2022531205A5 (https=) | ||
| JP2019504040A (ja) | 中等度〜重度のインフルエンザの処置 | |
| TW202206457A (zh) | 用於治療呼吸疾病之泛elr+ cxc趨化因子抗體 | |
| JP2022553703A5 (https=) | ||
| JP2023523096A5 (https=) | ||
| HK40129473A (en) | Methods for increasing forced expiratory volume in asthmatics using benralizumab | |
| HK40058739A (en) | Methods for increasing forced expiratory volume in asthmatics using benralizumab | |
| CN118021955A (zh) | 用于治疗il-17a介导的疾病或病症的方法和组合物 | |
| CN118922432A (zh) | 用于治疗细胞因子风暴的组合物和方法 | |
| HK40012636A (en) | Methods for increasing forced expiratory volume in asthmatics using benralizumab | |
| HK40012636B (en) | Methods for increasing forced expiratory volume in asthmatics using benralizumab | |
| HK40086385A (zh) | 脉冲递送气态药物的方法 | |
| CN115916820A (zh) | 用il6拮抗剂治疗包括covid-19肺炎在内的肺炎的方法 | |
| HK1225302A1 (en) | Methods for reducing exacerbation rates of asthma using benralizumab | |
| HK1225300B (en) | Methods for increasing forced expiratory volume in asthmatics using benralizumab |